Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)
Status:
Completed
Trial end date:
2020-02-06
Target enrollment:
Participant gender:
Summary
A prospective, open-label, multicentre phase-II trial to evaluate the efficacy and safety of
a sequential regimen of bendamustine followed by ofatumumab and ibrutinib followed by
ibrutinib and ofatumumab maintenance in CLL patients.